Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.

@article{Galvani2013EpidermalGF,
  title={Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.},
  author={Elena Galvani and Roberta Alfieri and Elisa Giovannetti and Andrea Cavazzoni and Silvia La Monica and Maricla Galetti and Claudia Fumarola and Mara A. Bonelli and Marco Mor and M Tiseo and Godefridus J. Peters and Pier Giorgio Petronini and Andrea Ardizzoni},
  journal={Current pharmaceutical design},
  year={2013},
  volume={19 5},
  pages={
          818-32
        }
}
Conventional chemotherapeutic regimens have reached an efficacy plateau against most solid tumors and deal with significant toxicity. Recently, the goal of oncologic research to improve outcome and reduce treatment-related side-effects has led to the development of novel anticancer treatments targeting specific proteins or genes involved in cancer growth and progression. In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…